secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2026-07-28T12:35:34+00:00
Accession:  0001213900-26-082007
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics appoints Bipin Dalmia as Chief Business Officer
--------------------------------------------------------------------

- Bipin Dalmia, PhD, MBA, appointed Chief Business Officer effective July 28, 2026.
- He brings nearly three decades of biopharmaceutical leadership, with expertise in NMIBC and corporate strategy.
- He will lead corporate strategy, commercial planning, and business development, reporting to CEO Sergio Traversa.
- His appointment supports advancement of NDV-01, Relmada's sustained-release intravesical therapy for NMIBC.
- He previously helped bring first FDA-approved intravesical gene therapy to bladder cancer patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390026082007/0001213900-26-082007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390026082007/ea0299449-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-082007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer